| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Coagulation factors (Substitution)| 1 | 2009 | Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. | 
| + | - | nl | Blood Transfus 7(4):325-34 (2009) |
| 2 | 2008 | [Clotting factor concentrates]. |
| + | - | nl | Hamostaseologie 28(5):387-99 (2008) |
| 3 | 2005 | [Replacement therapy of coagulation factor preparations: antithrombin, FFP, PPSB, FXIII, rFVIIa]. |
| + | - | nl | Hamostaseologie 25(2):209-12 (2005) |
| 4 | 2004 | [Clotting factor concentrates]. |
| + | - | nl | Hamostaseologie 24(4):286-97 (2004) |
| 5 | 2009 | The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. |
| + | - | nl | J Thromb Haemost 7(9):1446-56 (2009) |
| 6 | 2009 | Role of regulatory T cells in tolerance to coagulation factors. |
| + | - | nl | J Thromb Haemost 7 Suppl 1(-):88-91 (2009) |
| 7 | 2007 | Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. |
| + | - | nl | J Thromb Haemost 5 Suppl 1(-):143-50 (2007) |
| 8 | 2005 | Treatment of patients with acquired inhibitors. |
| + | - | nl | J Thromb Haemost 3(3):595-7 (2005) |
| 9 | 2004 | Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. |
| + | - | nl | J Thromb Haemost 2(7):1082-95 (2004) |
| 10 | 2003 | Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. |
| + | - | nl | J Thromb Haemost 1(6):1228-36 (2003) |
| 11 | 2010 | Clinical review: Fresh frozen plasma in massive bleedings - more questions than answers. |
| + | - | nl | Crit Care 14(1):202 (2010) |
| 12 | 2010 | Rationalizing the clinical use of frozen plasma. |
| + | - | nl | CMAJ 182(10):1019-20 (2010) |
